Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 10/2010

Open Access 01-10-2010 | Original Article

The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients

Authors: Barbara Mroczko, Magdalena Groblewska, Bogna Okulczyk, Bogusław Kędra, Maciej Szmitkowski

Published in: International Journal of Colorectal Disease | Issue 10/2010

Login to get access

Abstract

Purpose

Tumor cells, including colorectal cancer (CRC), are able to produce and release matrix metalloproteinase 9 (MMP-9) which is involved in tumor invasion and metastasis. Natural tissue inhibitors of matrix metalloproteinases (TIMPs) regulate activity of MMPs and stimulate tumor growth and malignant transformation. The aim of the present study was to compare the clinical significance of serum MMP-9 with TIMP-1 in the diagnosis of CRC patients and in the differentiation between colorectal adenoma (CA) and cancer.

Methods

Serum MMP-9 and TIMP-1 were measured in 75 CRC patients, 35 CA, and 70 healthy subjects using enzyme-linked immunosorbent assay. Concentrations of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) were determined by microparticle enzyme immunoassay.

Results

Serum levels of all proteins tested were significantly higher in CRC patients than in healthy subjects. Additionally, serum TIMP-1 was significantly higher in patients with CRC than in CA patients. Concentrations of TIMP-1 correlated with tumor stage, nodal involvement, presence of distant metastases, patients' survival, and tumor resectability. Diagnostic sensitivity of TIMP-1 was higher (61%) than those of other biomarkers (MMP-9, 55%; CEA, 39%; CA 19-9, 11%), and increased in combined use with MMP-9 (75%) or CEA (73%). The areas under receiver operating characteristic curves of TIMP-1 were larger than those of MMP-9.

Conclusions

Our findings suggest better usefulness of serum TIMP-1 than MMP-9 in the diagnosis of CRC, especially in the assessment of Duke's classification of tumor stage, survival of cancer patients, resectability of tumor, and in the differentiation between CA and cancer.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin (In press)
2.
3.
4.
Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166CrossRefPubMed
5.
Murray D, Morrin M, McDonnel S (2004) Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 24:489–494PubMed
6.
Kim TD, Song KS, Li G et al (2006) Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 6:211CrossRefPubMed
7.
Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T (2007) Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 97:971–977CrossRefPubMed
8.
Torii A, Kodera Y, Uesaka K et al (1997) Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 84:133–136CrossRefPubMed
9.
Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000) Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer-TIMP-1 as prognostic marker. Anticancer Res 20:1311–1316PubMed
10.
Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122:2050–2056CrossRefPubMed
11.
Lambert E, Dasse E, Haye B et al (2004) TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49:187–198CrossRefPubMed
12.
Hewitt RE, Brown KE, Corcoran M, Stetler-Stevenson WG (2000) Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line. J Pathol 192:455–459CrossRefPubMed
13.
Guedez L, Stetler-Stevenson WG, Wolff L et al (1998) In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102:2002–2010CrossRefPubMed
14.
McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ (1999) High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84:44–48CrossRefPubMed
15.
Lein M, Nowak L, Jung K et al (1999) Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue. Ann NY Acad Sci 878:544–546CrossRefPubMed
16.
Oberg A, Hoythya M, Taveli B, Stenling R, Lindmark G (2000) Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 20:1085–1091PubMed
17.
Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D (2003) Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today 33:885–892CrossRefPubMed
18.
Holten-Andersen MN, Stephens RW, Nielsen HJ et al (2000) High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6:4292–4299PubMed
19.
Yukawa N, Yoshikawa T, Akaike M et al (2004) Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Anticancer Res 24:2101–2105PubMed
20.
Yukawa N, Yoshikawa T, Akaike M et al (2007) Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 72:205–208CrossRefPubMed
21.
Waas ET, Hendriks T, Lomme RM, Wobbes T (2005) Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48:700–710CrossRefPubMed
22.
Herszényi L, Sipos F, Galamb O et al (2008) Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res 14:31–37CrossRefPubMed
23.
Tomita T, Iwata K (1996) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 39:1255–1264CrossRefPubMed
24.
Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56:190–196PubMed
25.
Jass JR, Sobin LH (1989) WHO international histological classification of tumors. Histological typing of intestinal tumors. Springer-Verlag, New York
26.
Mroczko B, Szmitkowski M, Okulczyk B (2003) Hematopoietic growth factors in colorectal cancer patients. Clin Chem Lab Med 41:646–651CrossRefPubMed
27.
Sato H, Kida Y, Mai M et al (1992) Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7:77–83PubMed
28.
Ogata Y, Miura K, Ohkita A, Nagase H, Shirouzu K (2001) Imbalance between matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 expression by tumor cells implicated in liver metastasis from colorectal carcinoma. Kurume Med J 48:211–218PubMed
29.
Gimeno-García AZ, Santana-Rodríguez A, Jiménez A et al (2006) Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Eur J Cancer 42:3246–3252CrossRefPubMed
30.
Holten-Andersen MN, Fenger C, Nielsen HJ et al (2004) Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer 40:2159–2164CrossRefPubMed
31.
Groblewska M, Mroczko B, Wereszczyńska-Siemiątkowska U et al (2008) Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46:1423–1428CrossRefPubMed
Metadata
Title
The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients
Authors
Barbara Mroczko
Magdalena Groblewska
Bogna Okulczyk
Bogusław Kędra
Maciej Szmitkowski
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 10/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-010-0991-9

Other articles of this Issue 10/2010

International Journal of Colorectal Disease 10/2010 Go to the issue

Letter to the Editor

Adiponectin and resistin: biomarker for colorectal cancer?

Original Article

Nuclear expression of CXCR4 is associated with advanced colorectal cancer

Original Article

Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers

Original Article

Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats

Letter to the Editor

Single-incision laparoscopic low anterior resection for rectal cancer

Letter to the Editor

Primary clear cell adenocarcinoma of the rectum: a case report